BHC(600721)2025-04-25 08:10Financial Performance - The company's operating revenue for Q1 2025 was ¥96,917,183.06, representing a 6.65% increase compared to ¥90,876,390.38 in the same period last year[4]. - Net profit attributable to shareholders was ¥20,720,859.94, a slight increase of 0.28% from ¥20,663,459.02 year-on-year[4]. - Basic earnings per share were ¥0.0540, a decrease of 0.18% from ¥0.0541 in the same period last year[4]. - Operating profit for Q1 2025 was ¥21,940,369.67, a marginal decrease of 0.2% from ¥21,980,744.79 in Q1 2024[16]. - Net profit for Q1 2025 was ¥20,720,859.94, slightly up from ¥20,663,459.02 in Q1 2024, reflecting a growth of 0.3%[17]. - Total operating costs for Q1 2025 were ¥69,790,602.60, an increase of 2.1% from ¥68,381,143.77 in Q1 2024[16]. - The company reported a decrease in sales revenue from goods and services in Q1 2025, totaling ¥69,873,787.38, down from ¥101,408,927.28 in Q1 2024, a decline of 31.1%[18]. Cash Flow and Investments - The net cash flow from operating activities decreased significantly to -¥17,265,723.64, compared to ¥15,106,346.65 in the previous year, marking a decline of 214.29%[4]. - Cash flow from operating activities in Q1 2025 was negative at -¥17,265,723.64, contrasting with a positive cash flow of ¥15,106,346.65 in Q1 2024[18]. - Investment activities resulted in a net cash outflow of -¥187,695,700.37 in Q1 2025, compared to -¥137,235,223.73 in Q1 2024, representing a 36.8% increase in cash outflow[19]. - The ending cash and cash equivalents balance for Q1 2025 was ¥67,613,090.24, down from ¥80,698,046.32 in Q1 2024[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,121,274,489.63, reflecting a 0.60% increase from ¥1,114,544,096.15 at the end of the previous year[5]. - The total liabilities decreased from RMB 355,962,377.86 to RMB 341,415,645.40 during the same period[15]. - The company's cash and cash equivalents decreased from RMB 272,048,128.25 to RMB 67,613,090.24[13]. - The accounts receivable increased from RMB 80,964,692.87 to RMB 105,719,538.73, reflecting a growth of approximately 30.6%[13]. - The company's total equity attributable to shareholders increased from RMB 758,581,718.29 to RMB 779,858,844.23[15]. - The company has a negative retained earnings of RMB -1,882,786,880.69 as of March 31, 2025, slightly improved from RMB -1,903,507,740.63 at the end of 2024[15]. Income and Other Revenue - Investment income rose by 147.39% compared to the same period last year, primarily due to increased profits from the associated company Kangyuan Huawai[7]. - Other income increased by 103.13% year-on-year, mainly from government subsidies received in the pharmaceutical sector[7]. - The company reported a significant increase in accounts receivable, which rose by 30.57% to ¥2,475,000, primarily due to increased receivables from pharmaceutical R&D[7]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,804[10]. - The company issued 111,700 stock options during the reporting period, increasing the total share capital from 384,032,635 shares to 384,144,335 shares[11]. Inventory and Contract Assets - The inventory increased from RMB 99,723,149.71 to RMB 104,429,899.38, indicating a rise of about 4.7%[13]. - The company's contract assets decreased from RMB 111,303,976.88 to RMB 99,429,233.77, a decline of approximately 10.6%[13].